The 3 Best Neuroscience Biotech Stocks to Buy Now

InvestorPlace07-19

Given the high bar to developing successful neuroscience treatments, the firms that do so are likely to be successfu. Here are three top biotech stocks to buy now. Vertex (VRTX): .Vertex’s non-opioid ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452429799?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-19 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2452429799","market":"us","top_or_hot":-1,"title":"The 3 Best Neuroscience Biotech Stocks to Buy Now","media":"InvestorPlace","content":"<div>\n<p>Given the high bar to developing successful neuroscience treatments, the firms that do so are likely to be successfu. Here are three top biotech stocks to buy now.\nVertex (VRTX): .Vertex’s non-opioid ...</p>\n\n<a href=\"https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The 3 Best Neuroscience Biotech Stocks to Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe 3 Best Neuroscience Biotech Stocks to Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-19 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Given the high bar to developing successful neuroscience treatments, the firms that do so are likely to be successfu. Here are three top biotech stocks to buy now.\nVertex (VRTX): .Vertex’s non-opioid ...</p>\n\n<a href=\"https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1267930573.SGD","symbol_name":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","start_time":0,"source_url":"https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/","article_id":"2452429799","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452429799","pubTimestamp":1721386800,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"Given the high bar to developing successful neuroscience treatments, the firms that do so are likely to be successfu. Here are three top biotech stocks to buy now.Vertex : .Vertex’s non-opioid painkiller looks very promising.NeuroOne : This small company has very impressive partners.Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it’s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.  Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","VERX":"Vertex, Inc.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","BK4532":"文艺复兴科技持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NMTC":"NEUROONE MEDICAL TECH","VRTX":"福泰制药","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","BK4566":"资本集团","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4082":"医疗保健设备","ZBH":"齐默巴奥米特控股","ESAIY":"Eisai Co., Ltd."},"translate_title":"立即购买的3只最佳神经科学生物技术股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZBH":1,"VRTX":1,"NMTC":1,"ESAIY":1,"VERX":0.9},"content_text":"Given the high bar to developing successful neuroscience treatments, the firms that do so are likely to be successfu. Here are three top biotech stocks to buy now.\nVertex (VRTX): .Vertex’s non-opioid painkiller looks very promising. \nEisai (ESAIY): The revenue generated by Eisai’s Alzheimer’s drug is likely to soar. \nNeuroOne (NMTC): This small company has very impressive partners. \n\n\n\n\n\n \n\nSource: Andrus Ciprian / Shutterstock.com\n\n\n\nProblems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it’s extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.  Further, the blood-brain barrier that stops damaging substances from entering our brains also prevents many drugs from impacting the organ. \nIn general, finding safe, effective drugs that insurers will pay for and that will be better than standard-of-care treatments is an extremely long, arduous process that’s unlikely to succeed. Given the enhanced difficulties involved with developing neurological treatments, companies in that space have an even harder road to traverse. \nBut the good news for investors is that, if companies do develop successful neurological drugs, they probably won’t face much tough competition. With that in mind, here are the three best neuroscience biotech stocks to buy now.\nVertex (VRTX)\nSource: Pavel Kapysh / Shutterstock.comPain is a neurological phenomenon. Consequently, Vertex’s (NASDAQ:VRTX) moderate-to-severe acute pain treatment, called suzetrigine, can be viewed as a neurological drug. Importantly, suzetrigine is a non-opioid pain medication, making it much less addictive than the powerful opioid pain treatments widely used today.\nVertex CEO Reshma Kewalramani explained that his company’s drug can “potentially fill the gap” between very safe but fairly weak painkillers and strong, opioid painkillers that can easily become addictive.\nIn a Phase-3 trial, suzetrigine successfully reduced patients’ surgical and non-surgical pain meaningfully more than a placebo. However, it failed to lessen patients’ pain significantly more than a combination of the opioid drug hydrocodone and acetaminophen. \nNonetheless, GlobalData has estimated that the drug will generate a significant $1.4 billion of revenue for Vertex in 2030. Other analysts believe that the treatment could generate multi-billion dollar peak annual revenue.\nVertex hoped to finish submitting the drug to the FDA for its approval as a treatment for “moderate to severe pain” by the end of last quarter.\nGiven the strong potential of Vertex’s non-addictive painkiller, I view it as one of the best biotech stocks to buy at this point. \nEisai (ESAIY)\nSource: PopTika / Shutterstock.comAs I’ve noted in previous columns, Eisai’s (OTCMKTS:ESAIY) Alzheimer’s drug, Leqembi, actually improved the cognition capabilities of 60% of patients thought to be in the early stages of the disease.\nMeanwhile, in May Eisai began a rolling submission of a Biologics License Application (BLA) for a subcutaneous version of the drug. If approved, this version, unlike the intravenous version that’s already being utilized, can be administered to patients in doctors’ offices and in homes. Additionally, the drug can be delivered more quickly via the subcutaneous mechanism than through IV, Eisai reported. Given these points, I believe that the demand for Leqembi will greatly increase after the subcutaenous version of it is released.\nBy fiscal 2026, Eisai predicts that the drug’s sales can reach almost $2 billion in its fiscal year that ends in March 2027 and $8.8 billion in its fiscal year that ends in March 2033. \nGiven Leqembi’s strong efficacy and the lack of strong competition in the Alzheimer’s treatment space, I believe that the drug’s revenue can significantly exceed those targets. Consequently, I believe that the company, which currently has a market capitalization of almost $12 billion, is significantly undervalued and is one of the best biotech stocks to buy now.\nNeuroOne Medical (NMTC)\nSource: everything possible / Shutterstock.comNeuroOne (NASDAQ:NMTC) develops products using thin film electrode technology. Its offerings are being used to facilitate electroencephalograms or EEGs which determine the extent of electrical activity in the brain. NeuroOne’s products are also being used in conjunction with  spinal cord stimulation and brain stimulation.\nProvoiding significant validation for NeurOne and its products, the firm partners with two very prestigious hospitals, Mayo Clinic and Cleveland Clinic. Additionally, the firm collaborates with a huge medical device company, Zimmer Biomet (NYSE:ZBH).\nAlso impressively, NeuroOne is only nine healthcare firms whose stock is owned by the Mayo Clinic.\nMoreover, NeuroOne is growing at an impressive rate as its product revenue jumped to $1.38 million last quarter compared to $466,000 during the same period a year earlier.\nOn the date of publication, Larry Ramer held a long position in ESAIY. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.  \nOn the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. \nLarry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer.Healthcare, Biotech\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/2024/07/the-3-best-neuroscience-biotech-stocks-to-buy-now/.\n©2024 InvestorPlace Media, LLC","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452429799"}